+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Early Phase 1
Age: 5Years - 50Years
All Genders
ID07695012

Feasibility of Autologous Anti-CD19 CAR-T Cell Therapy for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia in Children and Young Adults Aged 5 to 50

Led by Dr. Zaineb Akram · Updated on 2026-07-10

10

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Acute lymphoblastic leukemia ALL is the most common cancer in children and the second most frequent acute leukemia in adults. B-cell ALL makes up about 85% of ALL cases. In Pakistan, ALL is the most common blood cancer treated at major centers. While initial chemotherapy can lead to remission in most children, relapse rates remain significant, and adults generally have poorer outcomes. For patients with relapsed or refractory disease, new treatment options are needed due to limitations of standard therapies and transplants. This study evaluates an investigational autologous anti-CD19 CAR-T cell therapy developed and manufactured on-site at AFBMTC in Pakistan. The treatment involves collecting a patients own T cells, modifying them to target CD19 on leukemia cells, and then infusing them after chemotherapy to reduce leukemia burden. The therapy uses a lentiviral vector and an automated bioreactor system to produce the CAR-T cells. This pilot trial aims to assess the safety, feasibility, and early effectiveness of this approach in patients aged 5 to 50 years with relapsed or refractory B-cell ALL. Participants will undergo leukapheresis to collect T cells, followed by CAR-T cell manufacturing and infusion after receiving lymphodepleting chemotherapy. Researchers will monitor participants for safety and treatment effects over one year after infusion. Assessments include blood tests, bone marrow evaluation, and performance status checks. Long-term follow-up for up to 15 years will track gene therapy safety. The study measures safety and feasibility as its primary outcomes and involves regular clinical visits and monitoring throughout the treatment and follow-up periods.

CONDITIONS

Brief Title

CAR-T Cell Therapy for ALL

Research Team

N

Nadia Sial, Ph.D

M

Maryam Khan, MBBS, MRCP(UK), FCPS (Cl Haem)

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here